AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 5, 2026, 10:00 AM ET Altimmune will present RECLAIM Phase 2 pemvidutide results in alcohol use disorder as a late-breaking oral presentation at AASLD The Liver Meeting 2026 on November 9, 2026. AI-generated summary · Source: company release
Nasdaq: $ALTPemvidutide · liver diseasesPERFORMA Phase 3Clinical and dilution risk

ALT Stock Hub: Altimmune News, Pemvidutide and MASH Trials

Altimmune is developing pemvidutide across MASH, alcohol use disorder and alcohol-associated liver disease. Its next scheduled scientific presentations are at AASLD on November 7–9, 2026, including a late-breaking oral presentation of the RECLAIM alcohol use disorder data on November 9; RESTORE topline remains guided to H2 2027 and PERFORMA 52-week data to 2029. The balance sheet held approximately $519 million in cash and investments at June 30, 2026, following equity financings that enlarged the share count. A $10 million Hercules draw on October 27, disclosed October 29, adds a newer debt event to that dated financial picture.

Last updated: November 5, 2026Market reference: October 23, 2026 closeFinancial period: June 30, 2026Currency: USD
Research Library
The complete ALT research report
40 pages · Research as of October 26, 2026 · Dated snapshot, separate from this live hub
Get the report (PDF)
Next scientific catalyst · announced
AASLD · November 7–9, 2026

IMPACT 48-week responder and gastrointestinal-tolerability analyses and preclinical alcohol-intake data on November 7–8; on Monday, November 9, at 10:30 a.m. MT (12:30 p.m. ET), a late-breaking oral presentation of the RECLAIM Phase 2 data in alcohol use disorder, the first presentation of key RECLAIM data at an international scientific meeting. These are distinct from new Phase 3 efficacy results. RECLAIM late-breaker announcement → Company presentation schedule →

After AASLD: third-quarter 2026 financial results on Thursday, November 12, 2026, with a conference call at 8:30 a.m. ET to discuss the results and provide a business update. Company announcement. The two board appointments announced October 27 became effective November 2, 2026, according to that filing. Altimmune is scheduled to hold an End-of-Phase 2 meeting with the FDA in December 2026 to discuss a Phase 3 registrational program in alcohol use disorder.

ALT daily chart

ALT daily chart from Finviz
Source: Finviz. The chart updates independently of the dated figures below. Chart link is an affiliate link. Explore ALT on JC Just Charts →

ALT stock: dated key data

Closing price
$2.12
Nasdaq · October 23, 2026. Dated market reference.
Calculated market value
$412.4M
October 23 close × 194,517,701 shares reported August 7. Excludes warrants and awards.
Cash and investments
~$519M
June 30, 2026 · includes restricted cash and short- and long-term investments.
Pipeline
3 programs
Pemvidutide: PERFORMA in MASH, RECLAIM in AUD and RESTORE in ALD · August 12 update.
Q2 net loss
$22.8M
Quarter ended June 30, 2026. Net loss is not operating cash burn.
Common shares
194.52M
194,517,701 outstanding on August 7, 2026; 110,882,735 at December 31, 2025.
Common-stock warrants
75M at $3
June 30, 2026. Separately, 10.75M pre-funded warrants at $0.001 were outstanding.
Short interest
46.08M
September 30, 2026 settlement · 10.54 days to cover. About 23.7% of the dated August share count, calculated.

Financial and share data: June 30 Form 10-Q. Market references: Nasdaq historical prices and Nasdaq short interest. Market value uses a dated share count and is an estimate, not a current fully diluted valuation.

Where Altimmune stands now

Pemvidutide has progressed to Phase 3 in MASH, while two alcohol-related programs provide separate tests of the molecule. RECLAIM met its Phase 2 primary endpoint in July; RESTORE completed enrollment, with topline guided to H2 2027. The near-term AASLD presentations concern IMPACT analyses and preclinical evidence, plus a late-breaking oral presentation of the RECLAIM data on November 9, ahead of an End-of-Phase 2 meeting with the FDA scheduled for December 2026; the major prospective clinical readouts remain further away.

Main risk: the company remains dependent on an investigational molecule. A cash balance reported in June is not an October cash balance, and PERFORMA adds a prolonged, expensive development commitment. Financing strength must be assessed alongside dilution, debt terms and clinical uncertainty.

Constructive case

The June funding reserve supports multiple development programs. Further evidence could clarify pemvidutide’s liver and metabolic profile, while the positive RECLAIM result creates another development path. These are opportunities to test, not confirmed approvals.

Cautious case

Long development timelines, a much larger share base and warrant overhang can offset the value of the cash reserve. Phase 2 findings may not reproduce at pivotal scale, and a broader clinical program can increase spending before any commercial validation.

ALT stock news: six latest updates

Nov 5, 2026

Altimmune Announces RECLAIM Phase 2 Pemvidutide Alcohol Use Disorder Data at AASLD

A late-breaking abstract with results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder was accepted as an oral presentation at AASLD The Liver Meeting 2026. The presentation is scheduled for Monday, November 9, 2026, in Denver, Colorado, and will be presented by Henry R. Kranzler, M.D. Topline results announced in July 2026 showed pemvidutide achieved the primary endpoint of a statistically significant reduction in heavy drinking days per week compared with placebo. The Company is scheduled to hold an End-of-Phase 2 meeting with the FDA in December.

Nov 5, 2026

Altimmune to Report Third Quarter 2026 Financial Results on November 12, 2026

Altimmune, Inc. will report its third quarter 2026 financial results on Thursday, November 12, 2026. Management will host a conference call on November 12 to discuss the financial results and provide a business update. The call will be webcast live on the Investor Relations website, and a replay will be available for up to three months.

Oct 29, 2026

Hercules: $10 million drawn on October 27

The 8-K discloses Tranche Three under the $125 million facility. The interest-only period and amortization date extend to June 1, 2028; Qualified Cash must equal at least 60% of outstanding term-loan principal. The filing does not state the total principal after the draw. The $35 million principal in the June statements remains a separately dated figure.

Oct 27, 2026

Board appointments take effect November 2

The board appointed two directors and expanded from nine to eleven members, effective November 2. Three current directors will retire at the 2027 annual meeting. This is a governance update, separate from clinical results.

Oct 19, 2026

AASLD presentations scheduled for November 7–8

The program includes IMPACT gastrointestinal-tolerability and 48-week responder analyses, plus a preclinical alcohol-intake study in hamsters. The presentations do not constitute a new Phase 3 efficacy readout.

Oct 5, 2026

Officer filings report vesting and tax withholding

Forms 4 for the chief medical and financial officers report October 1 RSU vesting and shares withheld for taxes. They do not report discretionary open-market purchases.

ALT stock catalysts: dated milestones

  • November 2, 2026 · board appointmentsEffective date passed

    Two new directors took office, effective November 2 under the October 27 filing.

  • November 7–8, 2026 · AASLDAnnounced schedule

    November 7: preclinical oral presentation at 8:15 a.m. and IMPACT tolerability poster from 1–2 p.m. November 8: IMPACT responder oral presentation from 11:45 a.m.–noon. Times are Mountain Time.

  • November 9, 2026 · 12:30 p.m. ET · RECLAIM late-breakerAnnounced schedule

    Late-breaking oral presentation at AASLD in Denver (Late-Breaker Session 3, 10:30 a.m. MT) on the efficacy and safety of pemvidutide in adults with alcohol use disorder in the 24-week, randomized, double-blind, placebo-controlled RECLAIM Phase 2 trial, presented by Henry R. Kranzler, M.D. Announcement.

  • November 12, 2026 · Q3 2026 resultsCompany-announced call · 8:30 a.m. ET

    Third-quarter financial results and business update; the call is webcast on the investor relations website, with a replay for up to three months. Announcement.

  • December 2026 · FDA End-of-Phase 2 meetingCompany-scheduled meeting

    Meeting with the FDA to discuss the Phase 3 registrational program for pemvidutide in alcohol use disorder; no exact day has been given, and the meeting is not a regulatory decision. Announcement.

  • H2 2027 · RESTORE toplineCompany guidance

    Phase 2 ALD data; a development expectation, not a guaranteed result.

  • June 1, 2028 · loan amortization dateDisclosed loan terms

    Extended after the October 27 draw. Separate from the January 1, 2029 maturity stated in the June filing.

  • 2029 · PERFORMA 52-week dataCompany guidance

    Prospective Phase 3 MASH readout, subject to trial execution.

Pemvidutide: three development programs

MASH · Phase 3

PERFORMA

Global registrational study announced August 3, 2026. The company anticipates 52-week data in 2029. IMPACT Phase 2b analyses remain supportive evidence, distinct from the pivotal test.

AUD · Phase 2

RECLAIM

Positive topline was announced July 28, 2026, with the primary heavy-drinking-days endpoint met. The data are scheduled for a late-breaking oral presentation at AASLD on November 9, 2026, and the company is scheduled to hold an End-of-Phase 2 meeting with the FDA in December 2026 on a Phase 3 registrational program. Further regulatory feedback and development are needed; Phase 2 success is not approval.

ALD · Phase 2

RESTORE

Enrollment completion was announced in August 2026. Topline is guided to H2 2027. ALD and MASH are different clinical questions despite sharing the same investigational molecule.

Official pipeline →

ALT cash, debt and share dilution

The June reserve followed substantial 2026 equity financing. Common shares rose from 110.9 million at year-end 2025 to 194.5 million at the August 7 reporting date. At June 30, 75 million common-stock warrants at $3 and 10.75 million pre-funded warrants at $0.001 were separate potential sources of additional shares. Potential proceeds are conditional on exercise, and the dated cash balance should not be treated as a current runway calculation.

The June filing reported $35 million term-loan principal and January 1, 2029 maturity. The October 29 disclosure describes a subsequent $10 million draw and revised interest-only terms. These dates must remain separate: the later filing does not provide a refreshed total principal balance or a new quarter-end cash figure.

Merlintrader Health Score · ALT

2.9out of 5
Balance sheet and runway · 30%4.0 / 5

June cash reserve supports development; later spending and debt events remain separate.

Catalyst · 30%1.5 / 5

Major prospective clinical readouts are guided to H2 2027 and 2029.

Dilution · 20%2.5 / 5

Substantial share-count growth and outstanding warrants.

Liquidity · 10%3.5 / 5

Dated Nasdaq observations show active volume and material short interest.

Execution · 10%4.0 / 5

PERFORMA initiation, RECLAIM topline and RESTORE enrollment advanced the program; the RECLAIM data were selected for a late-breaking oral presentation at AASLD on November 9, 2026, and an End-of-Phase 2 FDA meeting is scheduled for December.

Assessment retained from October 26, 2026; reviewed November 5, 2026, after the Q3 results date and the RECLAIM late-breaking presentation were announced, with the scores unchanged. Weighted average: 2.90/5. The score describes financial and operational robustness over 12–18 months; it is not a valuation, price target or investment recommendation.

ALT red flags

  • Investigational drug exposure and concentration in one molecule.
  • Phase 2 results may not reproduce in larger, longer studies.
  • PERFORMA 52-week data are guided to 2029 and RESTORE topline to H2 2027, both subject to execution.
  • Equity dilution, warrants, debt covenants and rising trial costs.
  • Dated cash and share data are not current balances.
  • Competition, safety findings and regulatory requirements can change the program.

ALT Stock FAQ: Altimmune Questions Answered

When is the next ALT stock catalyst?

Altimmune schedules pemvidutide presentations at AASLD on November 7–8, 2026, covering IMPACT analyses and preclinical alcohol-intake findings, and a late-breaking oral presentation of the RECLAIM alcohol use disorder data on November 9 at 12:30 p.m. ET; an End-of-Phase 2 meeting with the FDA is scheduled for December 2026. Third-quarter 2026 results follow on November 12, with a conference call at 8:30 a.m. ET. Its major prospective readouts are RESTORE topline in H2 2027 and PERFORMA 52-week data in 2029. Those later windows are company expectations. AASLD presentations. RECLAIM late-breaker. Clinical program guidance.

Is Altimmune’s pemvidutide FDA approved?

No: Altimmune’s October 2026 AASLD announcement describes pemvidutide as investigational for MASH, alcohol use disorder and alcohol-associated liver disease. Fast Track and Breakthrough Therapy designations support development and regulatory interaction, while the program still requires successful trials and an approved application before commercialization. Investigational status and regulatory designations.

How much cash does Altimmune have, and how long will it last?

Altimmune held about $519 million cash and investments at June 30, 2026, after substantial equity financing; H1 operating cash use was $45.163 million. The June filing reported $35 million term-loan principal. A separate October 29 filing disclosed a later $10 million draw and revised interest-only terms, rather than a refreshed quarter-end cash balance. Larger clinical programs will affect future spending. Cash, financing and historical cash use. Later loan draw and amended terms.

Is ALT stock at risk of dilution?

Yes: Altimmune’s common shares increased from about 110.9 million at December 31, 2025 to 194.5 million on August 7, 2026. At June 30, 75 million common-stock warrants at $3 and 10.75 million pre-funded warrants at $0.001 were separate potential shares. Exercise conditions and issuance determine dilution; full potential warrant proceeds are not unconditional available cash. Share counts and warrant categories.

When does Altimmune report earnings?

Altimmune will report its third-quarter 2026 financial results on Thursday, November 12, 2026, and management will host a conference call at 8:30 a.m. ET that day to discuss the results and provide a business update, according to its November 5 announcement. Its latest quarterly update covered June 30, 2026 and was released on August 12. The scheduled AASLD presentations are scientific events. November 5 announcement. Company releases. Company events. Latest quarterly results.

What does Altimmune do?

Altimmune develops medicines for serious liver diseases. Its lead candidate pemvidutide combines glucagon and GLP-1 receptor activity and is being studied in MASH, alcohol use disorder and alcohol-associated liver disease. It remains a clinical-stage program without an approved commercial therapy. Company and lead candidate.

When will Altimmune report RESTORE and PERFORMA data?

Altimmune’s August 12, 2026 update guides RESTORE topline to H2 2027 and PERFORMA’s 52-week results to 2029. RESTORE tests pemvidutide in alcohol-associated liver disease, while PERFORMA is the Phase 3 MASH program. Their different populations, endpoints and follow-up periods require separate clinical assessments. Trial plans and expected timing.

What changed in Altimmune’s latest loan disclosure?

Altimmune’s October 29, 2026 filing reports a $10 million Tranche Three draw made on October 27. Meeting the milestone extended the interest-only period and amortization date to June 1, 2028 and set a qualified-cash covenant at 60% of outstanding term-loan advances. This adds a later borrowing event to the June balance-sheet context. Tranche Three draw and covenant.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ALT or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

This page is for educational and informational purposes only. It is not investment advice, medical advice, personalized financial advice, a recommendation, or a solicitation to buy or sell securities. Pemvidutide is investigational and has not been approved by the FDA for MASH, alcohol use disorder, alcohol-associated liver disease, obesity or any other indication. Clinical-stage biotechnology companies may experience extreme volatility, clinical failure, regulatory setbacks, financing risk and partial or total loss of invested capital. Forward-looking milestones are company guidance and may change. Readers should consult qualified healthcare professionals for medical decisions and appropriately authorized financial professionals for personalized financial matters.